Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612903 | 0.88 | ALOX5 (0.35) | MTNR1AMTNR1BALOX5EPHX2CNR1 | |
| SCHEMBL3887640 | 0.88 | HCAR2 (0.38) | MTNR1AMTNR1BHCAR2ALOX5EPHX2 | |
| SCHEMBL236629 | 0.87 | ALOX5 (0.34) | MTNR1AMTNR1BALOX5EPHX2CNR1 | |
| SCHEMBL612705 | 0.86 | FGFR3 (0.37) | MTNR1AMTNR1BALOX5EPHX2CNR1 | |
| SCHEMBL234786 | 0.86 | EPHX1 (0.39) | ALOX5EPHX2 | |
| SCHEMBL236861 | 0.85 | ALOX5 (0.37) | MTNR1AMTNR1BALOX5EPHX2 | |
| SCHEMBL237177 | 0.85 | MTNR1A (0.34) | MTNR1AMTNR1BALOX5EPHX2CNR1 | |
| SCHEMBL233923 | 0.84 | DDB1 (0.39) | NQO2KMT2A | |
| SCHEMBL238034 | 0.84 | MTNR1A (0.36) | MTNR1AMTNR1BALOX5EPHX2CNR1 | |
| SCHEMBL237636 | 0.84 | HCAR2 (0.38) | HCAR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452153-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-9056849-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20140323530-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8716529-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8450527-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8076516-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| EP-2111223-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009058216-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | MTNR1A 48/4885MTNR1B 20/4885NQO2 1586/4885 |
| US-20140323530-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | MTNR1A 48/4885MTNR1B 20/4885NQO2 1586/4885 |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | MTNR1A 48/4885MTNR1B 20/4885NQO2 1586/4885 |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | MTNR1A 48/4885MTNR1B 20/4885NQO2 1586/4885 |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | PDE6D, CLN6, AADAT | MTNR1A 48/4885MTNR1B 20/4885NQO2 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.